Table 2.

EGFR mutations associated with disease progression

NNumber of unique
MutationTherapy–response instancesPD responsesPatientsaStudiesbReferences
A763V111111
A859T222212, 13
Del19 A767-V769111111
Del19 unspecified + ins20 unspecified111114
Del19 unspecified + V769M111114
E709G + G719C111114
E711K111115
G719A + S768I222216, 17
G721D111118
G729R111115
I744M111119
I759T111120
Ins20 769-770insGVV111118
Ins20 A767-V769dupASV111117
Ins20 D770-N771insD111117
Ins20 P772-H773insYNP + H773Y111117
Ins20 S768-D770dupSVD434117
Ins20 SVD768-770323121
Ins20 unspecified333122
K806E111117
K860E111115
L703F111115
L747P222123
L777G111118
L838P + E868G111119
L858R + A871E111114
L858R + G719S323124
L858R + L747S (de novo)111114
L858R + L861P111115
L858R + T790M (de novo)656517, 18, 21, 25, 26
L858R + R776G111117
L861Q + G719S111111
N826Y111114
N842S111114
S768I + V769L111127
S784F111114
T847A + G863S111115
T847I111114
T790M (de novo)222225, 28
V774M111114
V802I111125
V852I111129

NOTE: Disease progression noted as a PD response as defined by the RECIST criteria (7), following treatment with EGFR TKI (gefitinib or erlotinib therapy).

  • aNumber of unique patients does not match the number of therapy–response entries as one patient may have been treated with EGFR TKIs in different lines of treatment and thus may have multiple associated therapy–response entries.

  • bNumber of unique studies refers to the number of different studies that encompass all of the patients with a particular mutation in DIRECT.